Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)

NCT05262517 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05262517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05262517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Temporomandibular Disorders (TMD)
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
May 5, 2022
Completion date
May 18, 2023
Enrollment
126 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

temporomandibular disorders (tmd)